An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

被引:336
作者
Carr, A [1 ]
Emery, S
Law, I
Puls, R
Lundgren, JD
Powderly, WG
Carr, B
Cooper, DA
Grinspoon, S
Ioannidis, J
Lewis, R
Law, M
Lichtenstein, K
Murray, J
Pizzuti, D
Rozenbaum, W
Schambelan, M
Moore, A
Miller, J
机构
[1] St Vincents Hosp, HIV Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia
[2] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[3] Hvidovre Univ Hosp, Copenhagen, Denmark
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Forum Collaborat HIV Res, Baltimore, MD USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Univ Ioannina, GR-45110 Ioannina, Greece
[8] Agouron Pharmaceut, San Diego, CA USA
[9] HIV Outpatient Study Ctr Dis Control & Prevent, Denver, CO USA
[10] US FDA, US Dept HHS, Washington, DC 20204 USA
[11] Bristol Myers Squibb Co, Princeton, NJ USA
[12] Hop Rothschild, F-75571 Paris, France
[13] Agence Natl Res SIDA, Paris, France
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
D O I
10.1016/S0140-6736(03)12656-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Lipodystrophy (peripheral lipoatrophy, central fat accumulation, and lipomatosis) is a common and disfiguring problem in adult patients with HIV-1 infection on antiretrovirals. However, an objective, validated definition of the disorder does not exist. We aimed to develop an objective, sensitive, specific, and broadly applicable case definition of HIV lipodystrophy. Methods In a case-control study, 1081 consecutive, HIV-infected, adult outpatients (261 [15%] women) without active AIDS were recruited from 32 sites worldwide. We classed patients with at least one moderate or severe subjective lipodystrophic feature, identified by lipodystrophy-specific physical examination and patient questionnaire, and apparent to both doctor and patient as cases (n=417). We classed patients with no such feature as controls (n=371), and patients without a clear diagnosis as non-assigned. We used objective clinical, metabolic, and body composition measurements to construct a logistic regression model with a subset of randomly selected cases and controls. The model was validated in the remaining patients. Findings A model including age, sex, duration of HIV infection, HIV disease stage, waist to hip ratio, anion gap, serum HDL cholesterol concentration, trunk to peripheral fat ratio, percentage leg fat, and intra-abdominal to extra-abdominal fat ratio had 79% (95% CI 70-85) sensitivity and 80% (95% Cl 71-87) specificity for diagnosis of lipodystrophy. Models that incorporated only clinical, or only clinical and metabolic variables had lower sensitivity and specificity than the inclusive model. Models for lipoatrophy, fat accumulation, and lipomatosis could not be developed since pure phenotypes occurred in fewer than 10% of patients with clinical diagnoses of these disorders. Interpretation Our objective case definition of HIV-associated lipodystrophy should improve assessment of lipodystrophy prevalence, risk factors, and pathogenesis; prevention and treatment approaches; and assist in diagnosis.
引用
收藏
页码:726 / 735
页数:10
相关论文
共 32 条
  • [1] Ammassari A, 2001, J ACQ IMMUN DEF SYND, V28, P445, DOI 10.1097/00042560-200112150-00006
  • [2] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [3] Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients
    Belloso, WH
    Quirós, RE
    Ivalo, SA
    Perman, MI
    Galich, AM
    Stern, LD
    Barcán, LA
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (01) : 104 - 111
  • [4] The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance
    Caron, M
    Auclair, R
    Vigouroux, C
    Glorian, M
    Forest, C
    Capeau, J
    [J]. DIABETES, 2001, 50 (06) : 1378 - 1388
  • [5] Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - A randomized trial
    Carr, A
    Workman, C
    Smith, DE
    Hoy, J
    Hudson, J
    Doong, N
    Martin, A
    Amin, J
    Freund, J
    Law, M
    Cooper, DA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02): : 207 - 215
  • [6] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1999, 353 (9170) : 2093 - 2099
  • [7] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
    Carr, A
    Samaras, K
    Burton, S
    Law, M
    Freund, J
    Chisholm, DJ
    Cooper, DA
    [J]. AIDS, 1998, 12 (07) : F51 - F58
  • [8] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
    Carr, A
    Miller, J
    Law, M
    Cooper, DA
    [J]. AIDS, 2000, 14 (03) : F25 - F32
  • [9] Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy
    Carr, A
    [J]. LANCET, 2002, 360 (9326) : 81 - 85
  • [10] Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors
    Dowell, P
    Flexner, C
    Kwiterovich, PO
    Lanes, MD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (52) : 41325 - 41332